We found some differences regarding the spectrum of those malignancies in anti-TNFα vs. DMARD treated patients: At study entry all nine cases with prior prostatic cancer were treated with biologics (seven with anti-TNFα and two with anakinra) whereas three patients with prior bladder cancer were found in the DMARD treated group and one patient was treated with anakinra. This evidence concerns the gene TNF and prostate carcinoma.